These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim. Zimrin A; Chumsri S Ann Hematol; 2013 Aug; 92(8):1145-6. PubMed ID: 23328792 [No Abstract] [Full Text] [Related]
45. [Recent advances in the treatment of idiopathic thrombocytopenic purpura]. Kurata Y Rinsho Ketsueki; 2007 May; 48(5):355-62. PubMed ID: 17571579 [No Abstract] [Full Text] [Related]
46. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Molineux G; Newland A Br J Haematol; 2010 Jul; 150(1):9-20. PubMed ID: 20298251 [TBL] [Abstract][Full Text] [Related]
47. Primary immune thrombocytopenia in adults: clinical practice versus management guidelines. Ng T; Gatt A; Smith M Postgrad Med J; 2017 Nov; 93(1105):645-646. PubMed ID: 28720688 [No Abstract] [Full Text] [Related]
53. Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data. Altomare I; Wasser J; Pullarkat V Am J Hematol; 2012 Oct; 87(10):984-7. PubMed ID: 22729832 [TBL] [Abstract][Full Text] [Related]
54. Sustaining platelet counts in chronic ITP. Nurden AT Lancet; 2011 Jan; 377(9763):358-60. PubMed ID: 20739056 [No Abstract] [Full Text] [Related]
55. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Cheng G; Saleh MN; Marcher C; Vasey S; Mayer B; Aivado M; Arning M; Stone NL; Bussel JB Lancet; 2011 Jan; 377(9763):393-402. PubMed ID: 20739054 [TBL] [Abstract][Full Text] [Related]
57. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. Kuter DJ Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568 [TBL] [Abstract][Full Text] [Related]
58. Thrombopoietin receptor agonists in the treatment of thrombocytopenia. Newland A Curr Opin Hematol; 2009 Sep; 16(5):357-64. PubMed ID: 19553811 [TBL] [Abstract][Full Text] [Related]
59. The new thrombopoietic agenda: impact on leukemias and MDS. Bussel JB Best Pract Res Clin Haematol; 2014; 27(3-4):288-92. PubMed ID: 25455280 [TBL] [Abstract][Full Text] [Related]